Database | Recombinant Antibodies And Mimetics Database

What can we help you find?

You are searching for:

Category A

Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Category B

Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation

Category C

Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation

Category D

Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation

Category E

Original source/host: Animal
Discovery method: immunisation-based selection post 2020
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Category F

Original source/host: Animal
Discovery method: immunisation-based selection post 2020
Production: Recombinant expression with animal-derived biomaterials used in production or final formulation

Category G

Original source/host: Unknown
Discovery method: Unknown
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Uncategorised Antibodies

Uncategorised Antibodies have Antibody/Binder Origins set in such a way as to prevent them from being assigned to a valid Antibody Category.

Click here to view all Antibody Category descriptions and to search directly by Antibody Category

Category A
- Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
- Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search
Category B
- Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
- Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
- Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
- Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation
Search
Category C
- Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
- Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
- Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
Search
Category D
- Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
- Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
- Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
Search
Category E
- Original source/host: Animal
- Discovery method: immunisation-based selection post 2020
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search
Category F
- Original source/host: Animal
- Discovery method: immunisation-based selection post 2020
- Production: Recombinant expression with animal-derived biomaterials used in production or final formulation
Search
Category G
- Original source/host: Unknown
- Discovery method: Unknown
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search

1141-1150 of 1245 results

Catalogue Number:

DHB94403

Category:

Research Grade Infliximab

Targets:	TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotypes/Mimetics:	IgG1, kappa
Host Species:	Other
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

DHD80802

Category:

Research Grade Isatuximab

Targets:	Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Host Species:	Other
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

DHD87601

Category:

Research Grade Itolizumab

Targets:	TP120, CD6, T12, T-cell differentiation antigen CD6
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

DHH28801

Category:

Research Grade Ixekizumab

Targets:	CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

DHC21001

Category:

Research Grade Labetuzumab

Targets:	Meconium antigen 100, CEACAM5, CEA, CD66e, Carcinoembryonic antigen-related cell adhesion molecule 5, Carcinoembryonic antigen
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

DHA30601

Category:

Research Grade Landogrozumab

Targets:	GDF-8, GDF8, MSTN, Myostatin, Growth/differentiation factor 8
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

DHE07702

Category:

Research Grade Lebrikizumab

Targets:	IL13, NC30, Interleukin-13, IL-13
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

DHG17603

Category:

Research Grade Lemzoparlimab

Targets:	Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-Kappa
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

DHE85401

Category:

Research Grade Leronlimab

Targets:	C-C CKR-5, CC-CKR-5, CMKBR5, HIV-1 fusion coreceptor, CHEMR13, CCR5, C-C chemokine receptor type 5, CD195, CCR-5
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

DHB65401

Category:

Research Grade Lifastuzumab

Targets:	Sodium/phosphate cotransporter 2B, Na(+)-dependent phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, Sodium-dependent phosphate transport protein 2B, NaPi3b, NaPi-2b, SLC34A2, Solute carrier family 34 member 2, Sodium-phosphate transport protein 2B
Species Reactivity:	Human
Application:	Other
Other Application:	Research Grade Biosimilar
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Viewing 1141-1150 of 1245 results

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.